ArticleWorld journal of gastrointestinal oncology2025
Medical travel patterns for hepatocellular carcinoma treatment in South Korea: National Health Insurance data from 2013 to 2021.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) remains a significant public health concern in South Korea even though the incidence rates are declining. While medical travel for cancer treatment is common, its patterns and influencing factors for patients with HCC are unknown.
aimTo assess medical travel patterns and determinants and their policy implications among patients with newly diagnosed HCC in South Korea.
methodsThis retrospective cohort study used the National Health Insurance Service database to identify patients with newly diagnosed HCC from 2013 to 2021. Medical travel was defined as receiving initial treatment outside one's residential region. Patient characteristics and regional trends were analyzed, and factors influencing medical travel were identified using logistic regression analysis.
resultsAmong 64808 patients 52.4% received treatment in the capital. This proportion increased to 67.4% when including the surrounding metropolitan area. Medical travel was significantly more common among younger and wealthier patients. Patients with greater comorbidity burden or liver cirrhosis were less likely to travel. While geographic distance influenced travel patterns, high-volume academic centers in the capital attracted patients nationwide regardless of proximity.
conclusionThis nationwide study highlighted the centralization of HCC care in the capital. This observation indicates that regional cancer hubs should be strengthened and promoted for equitable healthcare access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.